Pharma Globenewswire

Cannabinoid Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Domain | DelveInsight

22 January 2026

DelveInsight’s, “Cannabinoid Pipeline Insight, 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Cannabinoid pipeline landscape. It covers the Cannabinoid pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cannabinoid pipeline therapeutics assessment by

Uncategorised

PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to increase by 2034, estimates DelveInsight

22 January 2026

DelveInsight’s “Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Pulmonary Hypertension associated with Interstitial Lung Disease, historical and forecasted epidemiology, as well as the Pulmonary Hypertension associated with Interstitial Lung Disease

Uncategorised

Structural Heart Devices Market Poised for Significant Growth, Projected to Reach ~USD 25 Billion by 2032 Driven by Increasing Adoption of Minimally Invasive Therapies | DelveInsight

22 January 2026

DelveInsight’s Structural Heart Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Structural Heart Devices Companies market shares, challenges, Structural Heart Devices Market Drivers, barriers, trends, and key market Structural Heart Devices companies in the market. To

Uncategorised

Global Embolic Protection Devices Market Poised for Robust Expansion, Projected to Grow at a CAGR of ~8% Through 2032 | DelveInsight

22 January 2026

DelveInsight’s Embolic Protection Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Embolic Protection Devices Companies market shares, challenges, Embolic Protection Devices Market Drivers, barriers, trends, and key market Embolic Protection Devices companies in the market. To

Uncategorised

Erectile Dysfunction Devices Market Poised for Robust Growth, Expected to Expand at ~8% CAGR Through 2032 Driven by Increasing Global Demand and Technological Innovation | DelveInsight

22 January 2026

DelveInsight’s Erectile Dysfunction Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Erectile Dysfunction Devices Companies market shares, challenges, Erectile Dysfunction Devices Market Drivers, barriers, trends, and key market Erectile Dysfunction Devices companies in the market. To

Clinical Trials

Atossa Therapeutics’ (Z)-Endoxifen Achieves FDA Orphan Drug Designation for Duchenne Muscular Dystrophy

21 January 2026

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative therapies in oncology and rare disease indications, announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the

Clinical Trials·News·Reports

Next-Gen BTK Inhibitors Take Off! 30 Pharma Companies Ignite Clinical Momentum!

21 January 2026

The BTK inhibitors clinical development landscape is rapidly evolving, supported by strong scientific validation and expanding therapeutic ambition. Rising incidence of B-cell malignancies, autoimmune diseases, and neurological disorders is intensifying demand for targeted therapies, positioning BTK inhibitors (BTKi) as a cornerstone of

Market Insights

Urea Cycle Disorders Market Poised for Strong Expansion by 2034

21 January 2026

According to a recent DelveInsight report, the Urea Cycle Disorders (UCD) market is expected to witness substantial expansion through 2032, driven by increasing disease awareness, improved diagnostics, and a rapidly advancing therapeutic pipeline. The report, titled “Urea Cycle Disorders Market Insights, Epidemiology,

Clinical Trials

Eli Lilly’s Sofetabart Mipitecan Receives FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer

21 January 2026

Eli Lilly and Company announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to sofetabart mipitecan (LY4170156) for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (PROC) who have previously received

Latest

Cannabinoid Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Domain | DelveInsight

PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to increase by 2034, estimates DelveInsight

Structural Heart Devices Market Poised for Significant Growth, Projected to Reach ~USD 25 Billion by 2032 Driven by Increasing Adoption of Minimally Invasive Therapies | DelveInsight

Global Embolic Protection Devices Market Poised for Robust Expansion, Projected to Grow at a CAGR of ~8% Through 2032 | DelveInsight

Erectile Dysfunction Devices Market Poised for Robust Growth, Expected to Expand at ~8% CAGR Through 2032 Driven by Increasing Global Demand and Technological Innovation | DelveInsight

Atossa Therapeutics’ (Z)-Endoxifen Achieves FDA Orphan Drug Designation for Duchenne Muscular Dystrophy

Next-Gen BTK Inhibitors Take Off! 30 Pharma Companies Ignite Clinical Momentum!

Urea Cycle Disorders Market Poised for Strong Expansion by 2034

Eli Lilly’s Sofetabart Mipitecan Receives FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer

Recent Posts

Banner

Newsletter

Authors